Navigation Links
Webcast Alert: MicroRNA: The Year in Review
Date:12/9/2009

CARLSBAD, Calif., Dec. 9 /PRNewswire/ -- Regulus Therapeutics Inc. will host an educational Webinar featuring a discussion with leading microRNA scientists: Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, M.D., Ph.D. Professor at the Swiss Federal Institute of Technology. Dr. Tuschl will discuss the discovery of microRNA and its role as a master regulator of the genome, and Dr. Stoffel will discuss the elucidation of microRNA function in normal and disease states, and therapeutic strategies based on microRNA modulation.


What:      MicroRNA: The Year in Review

When:      3 p.m. EST on Monday, December 14

Where:     http://www.videonewswire.com/event.asp?id=64631

How:       Live over the Internet -- Simply log on at the address above.


      Contact:

                      Regulus Therapeutics
                      Garry E. Menzel, Ph.D.
                      (760)268-6811

                      Media
                      Heidi Chokeir, Ph.D.
                      Russo Partners, LLC
                      (619)528-2217
                      heidi.chokeir@russopartnersllc.com

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new class of therapeutics by working with a broad network of academic collaborators and leveraging oligonucleotide drug discovery and development expertise from Alnylam Pharmaceuticals and Isis Pharmaceuticals (Alnylam and Isis jointly formed Regulus in 2007). Regulus is advancing microRNA therapeutics towards the clinic in several areas including hepatitis C infection, cardiovascular disease and fibrosis, oncology, and immunology and inflammation. Regulus intellectual property estate contains both the fundamental and core patents in the field as well as over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In 2008, Regulus entered into a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. For more information, visit www.regulusrx.com.

Minimum Requirements to listen to broadcast:

The Windows Media Player software, downloadable free from http://www.microsoft.com and at least a 56Kbps connection to the Internet.

If you experience problems listening to the webcast, send an E-mail to: webcast@multivu.com.

SOURCE Regulus Therapeutics Inc.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NBTY To Webcast Presentation; Wedbush Securities California Dreamin Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009
2. Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications
3. Gen-Probe to Webcast Presentation at the 21st Annual Piper Jaffray Health Care Conference Today
4. Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
5. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
6. Sunrise to Host Conference Call and Webcast to Discuss Third-Quarter 2009 Financial Results
7. Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday, November 4, at 10 A.M. EST
8. NHP Announces Third Quarter Earnings Release Date and Webcast/Conference Call
9. Smart Balance to Host Webcast/Conference Call on 2009 Third-Quarter Results
10. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2010 Results
11. CBIZ Webcasts Third-Quarter 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at the ... The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will feature ...
(Date:1/23/2017)... ... 2017 , ... "ProRandom is a set of camera tools that allow video editors to integrate ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , With ProRandom, ... video footage. ProRandom works by using a virtual camera to create the illusion of ...
(Date:1/23/2017)... ... January 23, 2017 , ... “The Inn at the Mill”: a story of love and ... quest to become happy and content. , “The Inn at the Mill” is the ... in Germany and Vermont and is now living in Berks County on Crow Hill. ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of ... Father. “Some Infallible Characteristics of Christ” is the creation of published author, Rev. Dr. ... Baptist Church for thirteen years, a preacher for over nineteen, a pastor for over ...
(Date:1/22/2017)... ... 2017 , ... "Photo Cloud allows FCPX users to add favorited photos to ... ease," said Christina Austin - CEO of Pixel Film Studios. , To begin, ... timeline. Presets include scenes with one, three, four or five focus points. There are ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... -- The American Pharmacists Association (APhA) is excited about ... Underserved Areas Enhancement Act (H.R. 592) in ... previously introduced in the 114 th session of ... pharmacists and their patient care services. Sponsors ... (R-KY), G.K. Butterfield (D-NC), Tom Reed ...
(Date:1/23/2017)... Ahead of today,s trading session, Stock-Callers.com draws investors, attention ... the close: Kite Pharma Inc. (NASDAQ: KITE ), BioPharmX ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ). According to a ... January 20 th , 2017, down on the day by about ... now at: ...
(Date:1/23/2017)... WELLESLEY, Massachusetts , January 23, 2017 Longer ... solid growth in the global market for medical device technologies. BCC ... particularly in the Asia-Pacific region, should see strong ... coverage, and rising disposable incomes. Continue Reading ... ...
Breaking Medicine Technology: